角膜移植术前的抗（淋巴）血管生成预处理
[Anti(lymph)angiogenic preconditioning prior to keratoplasty].
作者信息
Cursiefen C, Regenfuss B, Hos D, Bucher F, Steven P, Heindl L M, Bock F
机构信息
Universitätsaugenklinik, Universität zu Köln, Kerpener Strasse 62, Köln.
出版信息
Klin Monbl Augenheilkd. 2013 May;230(5):500-4. doi: 10.1055/s-0032-1328500. Epub 2013 May 21.
PURPOSE
The aim of this study is to describe novel therapeutic concepts to promote graft survival in high-risk keratoplasty by targeting (lymph)angiogenesis in the transplant context.
METHODS
A PubMed literature search and our own clinical and experimental data are evaluated.
RESULTS
There are three options for anti(lymph)angiogenic preconditioning: a) primary prevention of neovascularisation during the disease process, b) secondary prevention by regressing established blood vessels prior to transplantation and (c) tertiary prevention through inhibition of post-keratoplasty neovascularisation.
CONCLUSION
Modern topical anti(lymph)angiogenic therapies seem to be able to reduce the risk of graft rejection especially in high-risk keratoplasty.
目的
本研究的目的是描述通过在移植背景下靶向（淋巴）血管生成来促进高危角膜移植中移植物存活的新治疗概念。
方法
对PubMed文献检索结果以及我们自己的临床和实验数据进行评估。
结果
抗（淋巴）血管生成预处理有三种选择：a）在疾病过程中对新生血管形成进行一级预防，b）在移植前通过使已形成的血管消退进行二级预防，以及c）通过抑制角膜移植术后新生血管形成进行三级预防。
结论
现代局部抗（淋巴）血管生成疗法似乎能够降低移植物排斥反应的风险，尤其是在高危角膜移植中。
Zotero 插件